Formosa Pharmaceuticals, Inc. (TPE:6838)
Taiwan
· Delayed Price · Currency is TWD 34.70
+0.55 (1.61%)
At close: Jun 10, 2025
Formosa Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Revenue | 16.15 | 143.36 | 31.17 | 1.32 | 28.53 | - | Upgrade
|
| Revenue Growth (YoY) | -89.84% | 359.89% | 2270.49% | -95.39% | - | - | Upgrade
|
| Cost of Revenue | 9.65 | 24.37 | 3.83 | 0.98 | 0.27 | - | Upgrade
|
| Gross Profit | 6.5 | 118.99 | 27.35 | 0.33 | 28.26 | - | Upgrade
|
| Selling, General & Admin | 64.48 | 60.8 | 40.2 | 25.53 | 20.65 | 17.31 | Upgrade
|
| Research & Development | 158.12 | 226 | 270.18 | 356.47 | 387.62 | 216.29 | Upgrade
|
| Operating Expenses | 230.42 | 294.62 | 310.38 | 382 | 408.27 | 233.6 | Upgrade
|
| Operating Income | -223.92 | -175.63 | -283.04 | -381.67 | -380.01 | -233.6 | Upgrade
|
| Interest Expense | -0.55 | -0.57 | -4.31 | -0.99 | -2.21 | -0.1 | Upgrade
|
| Interest & Investment Income | 23.19 | 21.18 | 12.42 | 0.47 | 0.06 | 0.48 | Upgrade
|
| Currency Exchange Gain (Loss) | -19.87 | -18.62 | 9.29 | -25.15 | 20.97 | 14.04 | Upgrade
|
| Other Non Operating Income (Expenses) | 1 | 1.03 | 0.09 | 0.75 | 0.01 | -0.25 | Upgrade
|
| EBT Excluding Unusual Items | -220.15 | -172.61 | -265.54 | -406.59 | -361.18 | -219.43 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.2 | -0.72 | Upgrade
|
| Other Unusual Items | 0 | -6.96 | -34.53 | - | -37.04 | - | Upgrade
|
| Pretax Income | -220.15 | -179.57 | -300.07 | -406.59 | -398.42 | -220.15 | Upgrade
|
| Income Tax Expense | 2.16 | 21.36 | 21.86 | -0.42 | 2.4 | -0.42 | Upgrade
|
| Earnings From Continuing Operations | -222.31 | -200.93 | -321.93 | -406.17 | -400.82 | -219.73 | Upgrade
|
| Minority Interest in Earnings | 0.02 | -0.08 | -0.03 | -0.1 | -0.06 | 0.07 | Upgrade
|
| Net Income | -222.29 | -201.01 | -321.96 | -406.27 | -400.88 | -219.66 | Upgrade
|
| Net Income to Common | -222.29 | -201.01 | -321.96 | -406.27 | -400.88 | -219.66 | Upgrade
|
| Shares Outstanding (Basic) | 145 | 141 | 124 | 105 | 92 | 71 | Upgrade
|
| Shares Outstanding (Diluted) | 145 | 141 | 124 | 105 | 92 | 71 | Upgrade
|
| Shares Change (YoY) | 12.24% | 13.48% | 18.00% | 13.70% | 31.19% | 8.70% | Upgrade
|
| EPS (Basic) | -1.53 | -1.43 | -2.59 | -3.86 | -4.33 | -3.12 | Upgrade
|
| EPS (Diluted) | -1.53 | -1.43 | -2.59 | -3.86 | -4.33 | -3.12 | Upgrade
|
| Free Cash Flow | -167.99 | -135.95 | -198.21 | -346.15 | -331.35 | -180.4 | Upgrade
|
| Free Cash Flow Per Share | -1.16 | -0.96 | -1.60 | -3.29 | -3.58 | -2.56 | Upgrade
|
| Gross Margin | 40.24% | 83.00% | 87.73% | 25.32% | 99.06% | - | Upgrade
|
| Operating Margin | -1386.51% | -122.51% | -907.98% | -29024.26% | -1332.01% | - | Upgrade
|
| Profit Margin | -1376.40% | -140.22% | -1032.84% | -30895.21% | -1405.18% | - | Upgrade
|
| Free Cash Flow Margin | -1040.19% | -94.83% | -635.85% | -26323.19% | -1161.46% | - | Upgrade
|
| EBITDA | -188.15 | -139.99 | -247.53 | -345.56 | -345.41 | -200.58 | Upgrade
|
| EBITDA Margin | - | -97.65% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 35.77 | 35.64 | 35.51 | 36.11 | 34.6 | 33.02 | Upgrade
|
| EBIT | -223.92 | -175.63 | -283.04 | -381.67 | -380.01 | -233.6 | Upgrade
|
| EBIT Margin | - | -122.51% | - | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.